Music therapy sits at the center of this dementia and brain health question.
Music therapy is not a feel-good supplement to dementia care — it is a clinically supported intervention that, for specific symptoms, performs comparably or better than antipsychotic medications, and without the risks that come with those drugs. For agitation, depression, and anxiety in dementia patients, the research is consistent enough that major health bodies now recommend non-pharmacological approaches like music therapy as first-line treatment before reaching for a prescription pad. That is a significant shift in clinical thinking, and it reflects how seriously the evidence is being taken. To understand what that means in practice, consider a randomized controlled trial that measured agitation in dementia patients receiving music therapy.
Over six weeks, agitation disruptiveness scores dropped from 20.81 to 12.59 — roughly a 40 percent reduction. In that same trial, patients in standard care saw their psychotropic medication prescriptions increase significantly more often than those receiving music therapy. The music was not replacing medication arbitrarily; it was reducing the behavioral symptoms that medication was typically prescribed to address. This article covers how that evidence stacks up across different symptom categories, where the limits of music therapy lie, and what the practical options look like for families and care teams making real decisions.
Table of Contents
- How Does Music Therapy Compare to Medication for Dementia Agitation?
- What Does the Evidence Show for Depression and Anxiety in Dementia Patients?
- Does Music Therapy Improve Cognitive Function in Dementia?
- What Are the Practical Options for Families and Care Teams?
- What Are the Limitations of Music Therapy Research?
- The NHS MELODIC Program and Where Clinical Practice Is Heading
- Where Is the Field Going?
- Conclusion
- Frequently Asked Questions
How Does Music Therapy Compare to Medication for Dementia Agitation?
Antipsychotic medications have long been used to manage agitation in dementia, but their track record is troubled. Beyond modest effectiveness, they carry documented risks including stroke, accelerated cognitive decline, and increased mortality. For a population already facing serious neurological deterioration, those risks are not trivial. This has pushed clinicians and researchers to look more carefully at non-pharmacological alternatives, and music therapy has emerged from that search with a reasonably strong evidence base specifically for agitation. The randomized controlled trial cited above — published in PMC — is one of the more rigorous data points available. An effect size of 0.50 is considered moderate in clinical research, and the finding that standard care led to more psychotropic prescriptions than the music therapy group (p = 0.02) is statistically meaningful.
A 2025 systematic review published through Taylor & Francis further confirmed that music interventions significantly alleviate agitation symptoms in older adults with dementia. The picture that emerges is not that music therapy eliminates agitation entirely, but that it reduces its frequency and intensity enough to matter — and often enough to avoid or delay pharmacological intervention. It is worth being direct about what antipsychotics are actually doing in this context. They sedate. They blunt behavioral responses without addressing the underlying distress driving those behaviors. Music therapy, particularly when individualized to a patient’s personal history and preferences, appears to engage a different mechanism — activating memory, emotion, and recognition pathways that remain relatively intact even in moderate-to-advanced dementia. That is not a mystical claim; it reflects what we know about how musical memory is stored and accessed in the brain, often surviving where other cognitive functions have declined.
What Does the Evidence Show for Depression and Anxiety in Dementia Patients?
Depression and anxiety are among the most common and least adequately treated aspects of dementia. They compound cognitive decline, reduce quality of life, and are difficult to treat pharmacologically in this population — antidepressants have shown limited benefit in dementia-related depression specifically, and carry their own side effect burdens in elderly patients. Music therapy has shown more consistent results here than in some other symptom categories. A 2025 meta-analysis published through Karger analyzing 24 randomized controlled trials found that music therapy patients showed significantly higher cognitive function, lower depression scores, and lower anxiety compared to control groups. The Cochrane Collaboration — known for rigorous evidence standards — found moderate-quality evidence for reduction in depression and behavioral symptoms, and low-quality evidence for anxiety improvement. Crucially, they reported no adverse effects across the studies reviewed.
That asymmetry matters enormously in clinical decision-making: even if music therapy’s effects on anxiety are modest and not yet firmly established, the risk profile is essentially zero. That cannot be said for benzodiazepines or antipsychotics. A network meta-analysis published through MDPI added a useful detail: not all music therapy is equivalent. Active music therapy involving singing was identified as having the greatest advantage for depressive symptoms specifically. This is an important caveat for care teams. Passive listening — playing music in the background — is not the same as a structured, active session led by a trained music therapist. The form of the intervention appears to affect the outcome, which means implementation quality matters if the goal is to replicate the research findings.
Does Music Therapy Improve Cognitive Function in Dementia?
Cognitive function is where expectations need to be carefully managed. Music therapy is not a treatment for the neurodegeneration underlying dementia. It does not slow the progression of Alzheimer’s disease, reverse memory loss, or restore lost cognitive capacity in any documented, sustained way. Anyone presenting it in those terms is overstating the evidence considerably. That said, systematic review data does show that music therapy interventions lasting at least 12 weeks have demonstrated positive effects on cognitive function — processing speed, attention, and certain memory tasks. Whether these reflect genuine neurological benefit or are a function of engagement, arousal, and mood improvement that allows patients to perform better on assessments is not entirely clear.
The effect appears to require ongoing intervention; it does not persist once sessions stop. That is a meaningful limitation for care planning. A ScienceDirect analysis of music therapy’s effects on cognition, quality of life, and neuropsychiatric symptoms found that results were inconsistent across studies — music therapy did not significantly improve agitation scores or quality of life in all studies reviewed. This heterogeneity reflects the difficulty in standardizing music therapy as an intervention. Session lengths in the research literature range from 20 to 90 minutes, music types vary widely, and settings range from individual sessions to group programs in care facilities. Comparing across these variations is inherently imprecise.
What Are the Practical Options for Families and Care Teams?
For families navigating dementia care, the question of music therapy versus medication is rarely an either/or decision in practice. Most patients in memory care settings are already on some form of pharmacological treatment by the time behavioral symptoms become severe. The more realistic question is whether music therapy can reduce reliance on those medications, or delay their introduction, rather than replace them entirely. The evidence suggests it can. The randomized controlled trial showing that music therapy patients required fewer new psychotropic prescriptions than standard care patients is directly relevant here. For families whose loved ones are experiencing early-to-moderate agitation or mood disturbances, pushing for a structured music therapy program before adding or increasing medication is a defensible, evidence-backed position to take with a care team.
It involves less risk, and it may work. The tradeoff is access. Music therapy delivered by a trained, credentialed therapist — as opposed to a care aide pressing play on a playlist — requires staffing and cost that many care facilities cannot easily absorb. Individualized music therapy, which tends to produce the strongest results, requires someone to learn the patient’s musical history, preferences, and emotional associations. That is labor-intensive. Group music programs are more scalable but show less consistent results. Families who want to pursue this seriously should ask specifically whether the facility employs or contracts with a board-certified music therapist, not just whether they “do music activities.”.
What Are the Limitations of Music Therapy Research?
The research supporting music therapy for dementia is genuinely encouraging, but it comes with methodological caveats that honest assessment requires acknowledging. The most significant is the impossibility of blinding. There is no placebo condition for music therapy in the way there is for a pill. Patients know they are receiving an intervention; observers often know which group a patient is in. Placebo and expectancy effects cannot be ruled out, and in a symptom category like agitation — which is partly measured through caregiver and observer ratings — that is a meaningful confound. Study heterogeneity is another persistent issue. The 2025 systematic and meta-analytic reviews noted significant variation across studies in session length, frequency, music type, therapist training, patient dementia stage, and outcome measures used.
When studies vary this much in design, pooling their results into aggregate conclusions requires caution. An effect found across highly heterogeneous studies may be real and robust, or it may reflect the averaging of very different interventions with very different effects. The Cochrane review’s designations of “moderate” and “low” quality evidence for different outcomes reflect this uncertainty honestly. Finally, most documented effects are not sustained without ongoing intervention. This is not unique to music therapy — medication effects also diminish without continued dosing — but it matters for how the intervention is presented to families. Music therapy is not a course of treatment that produces lasting change and then ends. It is an ongoing support that requires continued delivery to maintain its benefits. For patients in late-stage dementia or with very limited attention and engagement capacity, even that ongoing delivery may become difficult to sustain.
The NHS MELODIC Program and Where Clinical Practice Is Heading
One of the more significant recent developments is the NHS pilot of the MELODIC program in UK dementia wards — a structured initiative embedding live music therapy directly into inpatient care teams with the explicit goal of reducing drug use. Early results from the pilot, reported in 2025, showed improved wellbeing and reduced disruptive behavior among patients. A separate 2025 inpatient pilot study published through SAGE Journals assessed music-based interventions in hospital settings for people living with dementia, adding to an emerging body of work focused specifically on acute care environments rather than long-term residential settings.
These developments matter because they represent institutional adoption at a meaningful scale. When a national health system pilots a program to replace some antipsychotic use with music therapy in acute dementia care, it signals that the evidence threshold for taking this seriously has been crossed. The MELODIC program is not a research curiosity — it is an operational intervention designed to change prescribing behavior in clinical settings.
Where Is the Field Going?
The trajectory of dementia care is moving toward integrated, multimodal treatment plans that combine pharmacological management of disease progression with non-pharmacological management of behavioral and psychological symptoms. Music therapy fits into that second category more convincingly than almost any other non-drug intervention currently available, based on the current evidence base. What is needed now is better standardization.
Research that specifies clearly what kind of music therapy — individual versus group, active versus receptive, therapist-led versus technology-delivered — and at what dosage, produces which outcomes in which patient populations would allow for much more precise clinical recommendations. The 2025 meta-analysis and systematic reviews are steps in that direction. As that evidence base becomes more granular, music therapy’s place in dementia care protocols is likely to become more formally codified rather than remaining an optional add-on.
Conclusion
Music therapy has cleared the bar for clinical credibility in dementia care, particularly for agitation and depression. The evidence from randomized controlled trials, meta-analyses, and systematic reviews consistently shows meaningful symptom reduction with no adverse effects — a combination that compares favorably to antipsychotics, which offer modest benefits alongside serious risks. The 40 percent reduction in agitation disruptiveness documented in controlled research, the findings from a 24-RCT meta-analysis showing lower depression and anxiety in music therapy patients, and the NHS’s decision to embed music therapy into dementia ward care teams all point in the same direction.
The limitations are real and should not be glossed over: effects are not permanent, research heterogeneity makes precise recommendations difficult, and access to qualified music therapists is uneven. Music therapy does not slow neurodegeneration, and it is not effective for all patients in all settings. But for families and care teams looking to manage the behavioral and emotional symptoms of dementia with less pharmacological risk, the evidence is strong enough to make music therapy a serious first-line consideration rather than a nice-to-have afterthought.
Frequently Asked Questions
Can music therapy replace antipsychotic medication for dementia patients already on it?
Not necessarily on its own, and medication should never be stopped without medical supervision. However, structured music therapy has been shown to reduce the need for new or increased psychotropic prescriptions, and it may support a gradual reduction in existing medication under physician guidance.
Does the type of music matter in music therapy for dementia?
Yes, significantly. Individualized music therapy — where sessions are built around a patient’s personal musical history and preferences — consistently outperforms generic music programs. Music that carries autobiographical associations appears to engage emotional and memory systems more effectively than unfamiliar music.
How long does music therapy need to continue to show benefits?
For cognitive function specifically, systematic reviews indicate benefits appear with interventions lasting at least 12 weeks. Effects on agitation and mood can appear sooner, but they are generally not sustained once sessions stop, meaning ongoing delivery is necessary to maintain benefit.
Is there a difference between a music therapist and playing music for a dementia patient?
Yes, and it is an important distinction. Board-certified music therapists are trained to design and adapt therapeutic interventions based on patient response and clinical goals. Background music or recreational music activities provided by untrained staff may have some benefit but are not equivalent to formal music therapy and are not what most of the clinical research studied.
What symptoms does music therapy help with most reliably?
Agitation and depression have the strongest evidence base, with the Cochrane review finding moderate-quality evidence for both. Anxiety has lower-quality evidence supporting benefit. Cognitive function shows some improvement with longer interventions, but results are inconsistent across studies.
You Might Also Like
- What is the role of stem cell therapy in dementia research
- Is memantine effective for moderate to severe dementia
- What is the role of cholinesterase inhibitors in dementia treatment
For more, see Alzheimer’s Association.
